ConductScience.org, home

Paper42467361

CRISPR screening reveals NPC1L1 as a key driver of glioblastoma progression via cholesterol metabolic regulation.

Liu X and 16 others. MedScience, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. CRISPR screening reveals NPC1L1 as a key driver of glioblastoma progression via cholesterol metabolic regulation. Papers, record 42467361. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42467361

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
CRISPR screening reveals NPC1L1 as a key driver of glioblastoma progression via cholesterol metabolic regulation.
PubMed
Journal
MedScience
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-10-08
PubMed

Authors17

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Liu XXiao
2Yang GGuangzhao
3Qin HHaozhe
4Zhang QQi
5Guan ZZhihao
6Zhu MMaorong
7Zou CCheng
8Wang YYawen
9Wu YYuxin
10Yu DDuo
11Zheng DDan
12Li JJuan
13Gu JJintao
14Cao ZZhengcong
15Li ZZhengmin
16He YYalong
17Lin WWei

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Membrane Transport ProteinsMajor topic
GlioblastomaMajor topic
Central Nervous System NeoplasmsMajor topic
CholesterolMajor topic
Gene Expression Regulation, NeoplasticMajor topic
Humans
Clustered Regularly Interspaced Short Palindromic Repeats
Disease Progression
Ezetimibe
Anticholesteremic Agents
CD8-Positive T-Lymphocytes
Lymphocyte Activation
Antibodies, Monoclonal, Humanized
Animals
Mice
Disease Models, Animal

Source PubMed

Download CSV of topics

References34

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
138720342Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.J Hematol Oncol2024https://conductscience.org/library/papers/38720342PubMed
239329757Metabolic Reprogramming in Glioblastoma Multiforme: A Review of Pathways and Therapeutic Targets.Cells2024https://conductscience.org/library/papers/39329757PubMed
339236712Combinatorial targeting of glutamine metabolism and lysosomal-based lipid metabolism effectively suppresses glioblastoma.Cell Rep Med2024https://conductscience.org/library/papers/39236712PubMed
435189910Current applications and future perspective of CRISPR/Cas9 gene editing in cancer.Mol Cancer2022https://conductscience.org/library/papers/35189910PubMed
537646615Engineered Extracellular Vesicle-Delivered CRISPR/Cas9 for Radiotherapy Sensitization of Glioblastoma.ACS Nano2023https://conductscience.org/library/papers/37646615PubMed
631269428Macrophages and Metabolism in the Tumor Microenvironment.Cell Metab2019https://conductscience.org/library/papers/31269428PubMed
737991252Biomimetic Macrophage Membrane-Camouflaged Nanoparticles Induce Ferroptosis by Promoting Mitochondrial Damage in Glioblastoma.ACS Nano2023https://conductscience.org/library/papers/37991252PubMed
830622344Delivery technologies for cancer immunotherapy.Nat Rev Drug Discov2019https://conductscience.org/library/papers/30622344PubMed
936755314Exosome-transmitted circCABIN1 promotes temozolomide resistance in glioblastoma via sustaining ErbB downstream signaling.J Nanobiotechnology2023https://conductscience.org/library/papers/36755314PubMed
1031848472Mechanisms and regulation of cholesterol homeostasis.Nat Rev Mol Cell Biol2020https://conductscience.org/library/papers/31848472PubMed
1130684591CRISPR-Cas9 for cancer therapy: Opportunities and challenges.Cancer Lett2019https://conductscience.org/library/papers/30684591PubMed
1232348727Pooled In Vitro and In Vivo CRISPR-Cas9 Screening Identifies Tumor Suppressors in Human Colon Organoids.Cell Stem Cell2020https://conductscience.org/library/papers/32348727PubMed
1339979966Targeting GDF15 to enhance immunotherapy efficacy in glioblastoma through tumor microenvironment-responsive CRISPR-Cas9 nanoparticles.J Nanobiotechnology2025https://conductscience.org/library/papers/39979966PubMed
1429230226Cholesterol Metabolism in T Cells.Front Immunol2017https://conductscience.org/library/papers/29230226PubMed
1534261630Glioblastoma: clinical presentation, diagnosis, and management.BMJ2021https://conductscience.org/library/papers/34261630PubMed
1615871634Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions.Clin Pharmacokinet2005https://conductscience.org/library/papers/15871634PubMed
1732694690Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities.Nat Metab2020https://conductscience.org/library/papers/32694690PubMed
1838971819ATP6V0A1-dependent cholesterol absorption in colorectal cancer cells triggers immunosuppressive signaling to inactivate memory CD8+ T cells.Nat Commun2024https://conductscience.org/library/papers/38971819PubMed
1935023619Inhibition of NPC1L1 disrupts adaptive responses of drug-tolerant persister cells to chemotherapy.EMBO Mol Med2022https://conductscience.org/library/papers/35023619PubMed
2023091059Cholesterol and sphingomyelin drive ligand-independent T-cell antigen receptor nanoclustering.J Biol Chem2012https://conductscience.org/library/papers/23091059PubMed

See all 34 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42467361

GET https://conductscience.org/api/papers/v1/42467361/references?page=2